Quality of Life of Children Born with a Congenital Heart Defect.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
05 2022
Historique:
received: 02 09 2021
revised: 25 12 2021
accepted: 10 01 2022
pubmed: 17 1 2022
medline: 12 5 2022
entrez: 16 1 2022
Statut: ppublish

Résumé

To identify subgroups with a congenital heart defect (CHD) at risk of health-related quality of life (QoL) impairment at 8 years of age according to their medical and surgical management. From a prospective population-based cohort study, 598 patients with CHD were subdivided according to their medical and surgical management: (1) CHD followed-up in an outpatient clinic, (2) complete repair before age 3 years, (3) complete repair after age 3 years, (4) palliative repair, or (5) CHD with spontaneous resolution (reference subgroup). Self-reported QoL and parent-reported QoL were measured using the Pediatric Quality of Life Inventory version 4.0 (score range, 0-100) at age 8 years. Multivariable regression analysis and Cohen effect size were used to compare outcomes across the CHD groups. Self-reported and parent-reported QoL scores for the palliative repair subgroup were lower (β = -2.1 [95% CI, -3.9 to -0.2] and β = -16.0 [95% CI, -22.4 to -9.5], respectively), with a large effect size (δ = -0.9 [95% CI, -1.4 to -0.4] and δ = -1.3 [95% CI, -1.8 to -0.7], respectively). Parent-reported QoL scores for the complete repair after age 3 years subgroup were lower (β = -9.2; 95% CI, -15.0 to -3.5), with a large effect size (δ = -0.9; 95% CI, -1.4 to -0.5). Self-reported QoL scores for the complete repair before age 3 years subgroup was lower (β = -1.3; 95% CI, -1.9 to -0.6), with a small effect size (δ = -0.4; 95% CI, -0.6 to -0.2). The QoL of children with CHD who experienced a hospital intervention is reduced at age 8 years. Patient age at the last cardiac intervention might influence QoL at 8 years.

Identifiants

pubmed: 35033563
pii: S0022-3476(22)00003-8
doi: 10.1016/j.jpeds.2022.01.003
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

148-153.e5

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Neil Derridj (N)

Center of Research in Epidemiology and Statistics, Inserm, INRA, University of Paris, Paris, France; M3C-Pediatric Cardiology, Necker Enfants Malades, AP-HP, University of Paris, Paris, France. Electronic address: neil.derridj@inserm.fr.

Damien Bonnet (D)

M3C-Pediatric Cardiology, Necker Enfants Malades, AP-HP, University of Paris, Paris, France.

Johanna Calderon (J)

Physiology and Experimental Medicine Heart Muscles, UMR CNRS 9214, Inserm U1046, University of Montpellier, Montpellier, France; Department of Psychiatry, Harvard Medical School, Boston Children's Hospital, Boston, MA.

Pascal Amedro (P)

Paediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, IHU Liryc, Electrophysiology and Heart Modelling Institute, Bordeaux University Foundation, Pessac, France.

Nathalie Bertille (N)

Center of Research in Epidemiology and Statistics, Inserm, INRA, University of Paris, Paris, France.

Nathalie Lelong (N)

Center of Research in Epidemiology and Statistics, Inserm, INRA, University of Paris, Paris, France.

Francois Goffinet (F)

Center of Research in Epidemiology and Statistics, Inserm, INRA, University of Paris, Paris, France.

Babak Khoshnood (B)

Center of Research in Epidemiology and Statistics, Inserm, INRA, University of Paris, Paris, France.

Romain Guedj (R)

Center of Research in Epidemiology and Statistics, Inserm, INRA, University of Paris, Paris, France; Pediatric Emergency Department, Faculty of Medicine, AP-HP, Armand Trousseau Hospital, Sorbonne University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH